Exclusive Q&A: AveXis President David Lennon Talks Gene Therapy In 2019 [Investor's Business Daily]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Investors Business Daily
Related news Gene therapy is approaching a watershed moment, says AveXis President David Lennon. AveXis, which was acquired by Novartis ( NVS ) in May, hopes to become the second biotech with a marketed gene therapy in the U.S. Also in 2019, Lennon expects the gene therapy for spinal muscular atrophy — a debilitating disease that affects the spinal cord and can rob victims of the ability to walk, eat and even breathe — to gain approvals in Europe and Japan. AveXis recently dubbed it Zolgensma . If successful, Novartis' AveXis would follow Spark Therapeutics ( ONCE ), which gained approval in the U.S. in late 2017 for a gene therapy that treats a rare eye disorder . The tricky part about gene therapy lies in the price. Some analysts have suggested gene therapy drugs could cost millions of dollars. AveXis also is entering a highly competitive area of medicine. Biogen ( BIIB ) and Ionis Pharmaceuticals ( IONS ) have the first approved drug, Spinraza. Roche ( RHHBY ) and PTC Therapeutic
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Roche Sales Decline in Last Quarter of Pandemic Impact [BNN Bloomberg (Canada)]BNN Bloomberg
- Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria [Yahoo! Finance]Yahoo! Finance
- Why Novartis Stock Topped the Market on Tuesday [Yahoo! Finance]Yahoo! Finance
- FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors [Yahoo! Finance]Yahoo! Finance
- Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- NVS's page on the SEC website